Peter J Kniskern from 841 Patterson Dr, Lansdale, PA 19446, age 79, Phone: 6105844153

Process For Making Capsular Polysaccharides From Streptococcus Pneumoniae
view source
US Patent:

58471120, Dec 8, 1998
Filed:

Nov 14, 1997
Appl. No.:

8/970460
Inventors:

Peter J. Kniskern - Lansdale PA
William J. Miller - North Wales PA
Arpi Hagopian - Lansdale PA
Charlotte C. Ip - Blue Bell PA
John P. Hennessey - Dublin PA
Dennis J. Kubek - Salem WV
Pamela D. Burke - Lansdale PA
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

C07H 108
C08B 3700
C12P 1904
A61K 3909
US Classification:

536127
Abstract:

Type-specific capsular polysaccharide preparations from Streptococcus pneumoniae, having on average less than about 1000 oligosaccharide repeat units per molecule, polydispersities between 1. 0 and 1. 4, intrinsic viscosities between 0. 6 and 3. 0 dL/g, and less than 3% contamination of type-specific polysaccharide by group-specific C-polysaccharide, are produced by a novel process. The novel type specific polysaccharide products are useful in the preparation of vaccines, especially covalent conjugates comprising the novel polysaccharide linked to a T-cell stimulatory carrier protein. Vaccines comprising the novel polysaccharides are useful in the prevention of infection and of diseases associated with infection by Streptococcus pneumoniae.

Expression Of Fusion Protein Of Hiv Envelope And Hbsag
view source
US Patent:

51302470, Jul 14, 1992
Filed:

Sep 19, 1989
Appl. No.:

7/409180
Inventors:

Peter J. Kniskern - Lansdale PA
Arpi Hagopian - Lansdale PA
Pamela Burke - Lansdale PA
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

C12N 506
C12N 119
C12P 2106
C07H 2104
US Classification:

4352402
Abstract:

The present invention relates to recombinant fusion polypeptides of HIV envelope and HBsAg, suitable as vaccines against AIDS and/or ARC and hepatitis, as well as immunogens for inducting antibodies for passive protection or treatment of AIDS and/or ARC.

Pneumococcal Polysaccharide Conjugate Vaccine
view source
US Patent:

56230575, Apr 22, 1997
Filed:

May 20, 1994
Appl. No.:

8/246394
Inventors:

Stephen Marburg - Metuchen NJ
Richard L. Tolman - Warren NJ
Peter J. Kniskern - Lansdale PA
William J. Miller - North Wales PA
Arpi Hagopian - Lansdale PA
Charlotte C. Ip - Blue Bell PA
John P. Hennessey - Dublin PA
Dennis J. Kubek - Salem WV
Pamela D. Burke - Lansdale PA
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

C07K 1702
A61K 39385
US Classification:

530404
Abstract:

A novel conjugate vaccine comprising partially hydrolyzed, highly purified, capsular polysaccharide (Ps) from Streptococcus pneumoniae bacteria (pneumococci, Pn) linked to an immunogenic carrier protein, is produced by a new process. The conjugate is useful in the prevention of pneumococcal infections. Vaccines comprising a mixture of from one to ten different pneumococcal polysaccharide-immunogenic protein (Pn-Ps-PRO) conjugates induce broadly protective recipient immune responses against the cognate pathogens from which the polysaccharide components are derived. Young children and infants younger than 2 years old, normally unable to mount a protective immune response to the Pn-Ps alone, exhibit protective immune responses upon vaccination with these Pn-Ps-PRO conjugates.

Meningitis Vaccine
view source
US Patent:

42647649, Apr 28, 1981
Filed:

Sep 24, 1979
Appl. No.:

6/078430
Inventors:

Peter J. Kniskern - Sayreville NJ
Arpi Hagopian - Sayreville NJ
Dennis J. Carlo - Middlessex NJ
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

C07G 300
US Classification:

536 1
Abstract:

A high molecular weight capsular polysaccharide from H. influenza type b is an effective immunogenic agent against infection caused by the H. influenza type b bacterium.

Meningitis Vaccine
view source
US Patent:

43070809, Dec 22, 1981
Filed:

Sep 22, 1980
Appl. No.:

6/189416
Inventors:

Peter J. Kniskern - Sayreville NJ
Arpi Hagopian - Sayreville NJ
Dennis J. Carlo - Middlesex NJ
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

A61K 3900
A61K 39102
US Classification:

424 92
Abstract:

A high molecular weight capsular polysaccharide from H. influenza type b is an effective immunogenic agent against infection caused by the H. influenza type b bacterium.

Covalently-Modified Bacterial Polysaccharides, Stable Covalent Conjugates Of Such Polysaccharides And Immunogenic Proteins With Bigeneric Spacers And Methods Of Preparing Such Polysaccharides And Conjugataes And Of Confirming Covalency
view source
US Patent:

48823171, Nov 21, 1989
Filed:

Jun 18, 1987
Appl. No.:

7/063607
Inventors:

Stephen Marburg - Metuchen NJ
Peter J. Kniskern - Lansdale PA
Richard L. Tolman - Warren NJ
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

A61K 3702
A61K 3902
C07K 1504
US Classification:

514 54
Abstract:

Covalently modified bacterial polysaccharides and proteins; covalent conjugates of such polysaccharides linked by a bigeneric spacer, which permits proof of covalency and facilitates purification of conjugated materials, with immunogenic bacterial membrane or other proteins, which conjugates are useful components of bacterial vaccines; and methods of preparing such polysaccharides, proteins and conjugates and of confirming the covalency of the linkage between polysaccharides and proteins.

Hepatitis B Virus Surface Proteins With Reduced Host Carbohydrate Content
view source
US Patent:

56143842, Mar 25, 1997
Filed:

Jan 4, 1995
Appl. No.:

8/368287
Inventors:

Peter J. Kniskern - Lansdale PA
Arpi Hagopian - Lansdale PA
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

C12P 2102
C12N 119
A61K 3929
US Classification:

435 693
Abstract:

In order to produce hepatitis B virus (HBV) surface proteins in the form of particles with substantially reduced entrapped carbohydrate content, DNA encoding the HBV surface proteins was expressed in a recombinant yeast host which is deficient in its ability to glycosylate proteins. These HBV surface proteins display the antigenie sites genetically encoded by the S domain of the HBV virion envelope open reading frame and contains substantially reduced levels of entrapped carbohydrate when compared with HBsAg particles produced in "wild-type" yeast cells. These particles are useful as a vaccine for both the active and passive treatment or prevention of disease and/or infection caused by HBV or other agents serologically related to HBV.

Method Of Obtaining An Antigenic Fraction From Bordetella Bronchiseptica
view source
US Patent:

42502659, Feb 10, 1981
Filed:

Oct 15, 1979
Appl. No.:

6/084973
Inventors:

Dennis J. Carlo - Rahway NJ
Arpi Hagopian - Sayreville NJ
Peter J. Kniskern - Sayreville NJ
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

C07G 700
US Classification:

435272
Abstract:

A sub-cellular antigenic fraction of Bordetella bronchiseptica protects against the incidence and severity of swine atropic rhinitis.